Astellas gains three cancer drugs with $405m Potenza buy
Jo Taylor moves to Cello Health Communications
Biotech hopes for IPO or big pharma deal to fund phase 3
The FDA has granted Breakthrough Therapy Designation to enfortumab vedotin, an antibody-drug conjugate (ADC) being developed by Seattle Genetics and Astellas.
Japanese pharma swoops after strong phase 2a results.
UK awards first to introduce a real-world evidence category.